Clotilde Wiel

Dr. Clotilde Wiel

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
ZZZhiyuan V. Zou
Zhiyuan V. Zou
KBKristell Le Gal Beneroso
Kristell Le Gal Beneroso
Ahmed Ezat El ZowalatyAhmed Ezat El Zowalaty
Ahmed Ezat El Zowalaty
LPLara E. Pehlivanoglu
Lara E. Pehlivanoglu
VGViktor Garellick
Viktor Garellick
PLPer Lindahl
Per Lindahl
Dietary antioxidants and supplements are widely used to protect against cancer, even though it is now clear that antioxidants can promote tumor progression by helping cancer cells to overcome barriers of oxidative stress. Although recent studies have, in great detail, explored the role of antioxidants in lung and skin tumors driven by RAS and RAF mutations, little is known about the impact of antioxidant supplementation on other cancers, including Wnt-driven tumors originating from the gut. Here, we show that supplementation with the antioxidants N-acetylcysteine (NAC) and vitamin E promotes intestinal tumor progression in the ApcMin mouse model for familial adenomatous polyposis, a hereditary form of colorectal cancer, driven by Wnt signaling. Both antioxidants increased tumor size in early neoplasias and tumor grades in more advanced lesions without any impact on tumor initiation. Importantly, NAC treatment accelerated tumor progression at plasma concentrations comparable to those obtained in human subjects after prescription doses of the drug. These results demonstrate that antioxidants play an important role in the progression of intestinal tumors, which may have implications for patients with or predisposed to colorectal cancer.

20 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Ella EklundElla Eklund
Ella Eklund
CWClotilde Wiel
Clotilde Wiel
HFHenrik Fagman
Henrik Fagman
Levent M. AkyürekLevent M. Akyürek
Levent M. Akyürek
SRSukanya Raghavan
Sukanya Raghavan
VSVolkan Sayin
Volkan Sayin
There is an urgent need to identify new predictive biomarkers for treatment response to both platinum doublet chemotherapy (PT) and immune checkpoint blockade (ICB). Here, we evaluated whether treatment outcome could be affected by KRAS mutational status in patients with metastatic (Stage IV) non-small cell lung cancer (NSCLC). All consecutive patients molecularly assessed and diagnosed between 2016–2018 with Stage IV NSCLC in the region of West Sweden were included in this multi-center retrospective study. The primary study outcome was overall survival (OS). Out of 580 Stage IV NSCLC patients, 35.5% harbored an activating mutation in the KRAS gene (KRASMUT). Compared to KRAS wild-type (KRASWT), KRASMUT was a negative factor for OS (p = 0.014). On multivariate analysis, KRASMUT persisted as a negative factor for OS (HR 1.478, 95% CI 1.207–1.709, p < 0.001). When treated with first-line platinum doublet (n = 195), KRASMUT was a negative factor for survival (p = 0.018), with median OS of 9 months vs. KRASWT at 11 months. On multivariate analysis, KRASMUT persisted as a negative factor for OS (HR 1.564, 95% CI 1.124–2.177, p = 0.008). KRASMUT patients with high PD-L1 expression (PD-L1high) had better OS than PD-L1highKRASWT patients (p = 0.036). In response to first-line ICB, KRASMUT patients had a significantly (p = 0.006) better outcome than KRASWT patients, with a median OS of 23 vs. 6 months. On multivariable Cox analysis, KRASMUT status was an independent prognostic factor for better OS (HR 0.349, 95% CI 0.148–0.822, p = 0.016). kRAS mutations are associated with better response to treatment with immune checkpoint blockade and worse response to platinum doublet chemotherapy as well as shorter general OS in Stage IV NSCLC.

11 March 2026 in Nature
Verified
Journal Article
Open access
APAngana A. H. Patel
Angana A. H. Patel
JDJozefina J. Dzanan
Jozefina J. Dzanan
KAKevin X. Ali
Kevin X. Ali
Ella EklundElla Eklund
Ella Eklund
SASamantha W. Alvarez
Samantha W. Alvarez
VSVolkan Sayin
Volkan Sayin
Lung cancer predominantly affects older individuals, yet how physiological ageing influences tumour evolution remains poorly understood 1 . Here we show that ageing reprograms the evolutionary trajectory of KRAS -driven lung adenocarcinoma, limiting primary tumour growth while promoting metastatic dissemination through epigenetic activation of the integrated stress response (ISR). The ISR effector ATF4 drives epithelial and metabolic plasticity, conferring metastatic competence. Mechanistically, aged tumour cells show increased sensitivity to the PERK–eIF2α arm of the unfolded protein response, sustaining persistent ATF4 signalling. Targeting ISR–ATF4 genetically or pharmacologically abolishes these adaptations and limits dissemination, whereas ATF4 overexpression alone is sufficient to induce metastasis. The ageing–ATF4 axis imposes a dependency on glutamine metabolism, revealing a therapeutically actionable vulnerability. Clinical analyses confirm that ATF4 is enriched in aged tumours and correlates with poor survival and advanced-stage disease. Collectively, these results define epigenetic ISR–ATF4 activation as a causal driver of lineage plasticity and metastasis in aged tumours, revealing a therapeutic opportunity in older patients with lung adenocarcinoma, the most common yet understudied subset of lung cancer.

22 January 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
KBKristell Le Gal Beneroso
Kristell Le Gal Beneroso
CWClotilde Wiel
Clotilde Wiel
MIMohamed Ibrahim
Mohamed Ibrahim
MHMarcus Henricsson
Marcus Henricsson
VSVolkan Sayin
Volkan Sayin
MBMartin Bergo
Martin Bergo
Cancer cells produce high levels of mitochondria-associated reactive oxygen species (ROS) that can damage macromolecules, but also promote cell signaling and proliferation. Therefore, mitochondria-targeted antioxidants have been suggested to be useful in anti-cancer therapy, but no studies have convincingly addressed this question. Here, we administered the mitochondria-targeted antioxidants MitoQ and MitoTEMPO to mice with BRAF-induced malignant melanoma and KRAS-induced lung cancer, and found that these compounds had no impact on the number of primary tumors and metastases; and did not influence mitochondrial and nuclear DNA damage levels. Moreover, MitoQ and MitoTEMPO did not influence proliferation of human melanoma and lung cancer cell lines. MitoQ and its control substance dTPP, but not MitoTEMPO, increased glycolytic rates and reduced respiration in melanoma cells; whereas only dTPP produced this effect in lung cancer cells. Our results do not support the use of mitochondria-targeted antioxidants for anti-cancer monotherapy, at least not in malignant melanoma and lung cancer.

24 April 2026 in Redox Biology
Verified
Journal Article
Open access
KAKevin X. Ali
Kevin X. Ali
DKDonika Klenja-Skudrinja
Donika Klenja-Skudrinja
MHMaureen Higgins
Maureen Higgins
DWDavid Walker
David Walker
YSYumna Sharaf
Yumna Sharaf
LVLaureano De la Vega
Laureano De la Vega
BACH1 is a transcriptional regulator that modulates various cytoprotective pathways. Among these pathways BACH1 regulates cellular oxidative stress responses by suppressing the expression of cytoprotective genes. Dysregulated BACH1 activity has been implicated in a range of pathologies, including chronic inflammatory diseases, fibrosis, and cancer, making it a promising therapeutic target. However, BACH1 remains an underexploited drug target, with limited pharmacological inhibitors available. We have developed a novel luciferase-based reporter cell line enabling quantitative, high-throughput assessment of BACH1 inhibition. Using this platform, we rigorously screened two small-molecule libraries with 2046 compounds and identified four structurally distinct compounds that robustly inhibit BACH1 function. Notably, these compounds also activate transcription factor NRF2, suggesting the potential for a broader modulation of oxidative stress pathways. Importantly, we demonstrate that commonly used 2D migration assays may fail to detect phenotypes consistent with BACH1 inhibition, resulting in false negatives. In contrast, we establish that 3D invasion assays more robustly capture anti-invasive effects of BACH1 functional inhibition. Using this 3D system, we validate the identified compounds as potent suppressors of lung cancer cell invasion in vitro. This study delivers a novel screening platform for BACH1-targeted drug discovery, and challenges current in vitro standards by establishing 3D invasion assays as a more accurate functional readout for BACH1-targeting compounds. Additionally, it identifies new dual functional BACH1 inhibitors/NRF2 activators, offering novel chemical scaffolds for the development of anti-metastatic therapies and potentially treatments for diseases driven by oxidative stress and inflammation.

5 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
APAngana A.H. Patel
Angana A.H. Patel
JDJozefina Dzanan
Jozefina Dzanan
KAKevin X. Ali
Kevin X. Ali
EEElla A. Eklund
Ella A. Eklund
SASamantha W. Alvarez
Samantha W. Alvarez
VSVolkan Sayin
Volkan Sayin
Lung cancer is primarily a disease of the elderly. Despite shared molecular changes between aging and cancer 1 – such as permissive chromatin states and deregulated protein homeostasis – studies on physiologically aged models of human lung cancer are lacking. Here, we show that aging alters the progression of KRAS-driven non-small cell lung cancer (NSCLC), promoting metastasis while suppressing primary lung tumor growth. Clinically, a multicenter analysis of all consecutively diagnosed NSCLC cases in Western Sweden over a 3-year period confirmed increased metastasis and smaller primary tumor size with age in KRAS-driven NSCLC. In addition, primary lung tumor cultures derived from older mice demonstrated an increased metastatic phenotype. Unbiased transcriptomic and epigenomic analyses identified ATF4, a major arm of the unfolded protein response (UPR), as a driver of aging-induced lung cancer metastasis. Furthermore, we found that the age-associated increase in ATF4 fuels metastatic dissemination through metabolic rewiring, including increased glutaminolysis. Finally, we report that pharmacological inhibition of glutaminase effectively suppressed aging-induced metastasis. Our findings suggest a novel adjuvant therapy for human lung cancer by targeting aging-induced metabolic plasticity, highlighting the need to consider the biology of aging in the development of cancer therapy.